FDA
-
-
-
-
-
-
-
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
-
-
-
-
-
-
-
Precision BioSciences gets FDA fast track for DMD gene therapy
-
-
-
-
-
-
-
iECURE Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ECUR-506 for Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
-
-
-
-
-
-
-
Precision BioSciences gets FDA orphan drug designations for DMD treatment
-
-
-
-
-
-
-
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
-
328,348 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

